NCODA Logo

NEWS

Advancements in Patient-Centered Care

Stay up to date with the latest advancements in oral oncolytics, medically-integrated oncology, and cancer care best practices.

Miami Cancer Institute

September 17, 2019

MISSION STATEMENT/PHILOPSOPHY: Mission: Miami Cancer Institute provides comprehensive care, to patients with cancer and their families, in a multi-disciplinary setting, with the most innovative, evidence-based approaches available. We focus on compassionate care, delivered in a timely manner, with ready access to highly skilled and professional teams of caregivers. Vision: Miami Cancer Institute strives to be […]
read more

Celgene announces Phase 3 successes for CC-486 for use as maintenance therapy in Acute Myeloid Leukemia.

September 13, 2019

Top-line analysis showed a highly statistically significant and clinically meaningful improvement in overall survival for CC-486 Celgene plans regulatory submissions beginning in 1H 2020 SUMMIT, N.J.–(BUSINESS WIRE)– Celgene Corporation (NASDAQ: CELG) today announced top-line results from the international phase 3, randomized, double-blind, placebo-controlled study, QUAZAR AML-001. The study evaluated the efficacy and safety of investigational […]
read more

Medically integrated pharmacies make patient care more efficient

September 9, 2019

Loren Bonner, senior editor As more patients with cancer are treated with oral chemotherapy drugs, a new way of dispensing is slowly becoming more popular. Medically integrated dispensing, or medically integrated pharmacies, may not be known to many yet. However, if the desire is to receive more personal and coordinated care, patients with cancer should become […]
read more

U.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis

August 29, 2019

The FDA recently approved Inrebic® (Fedretinib) for Myelofibrosis, the first new treatment in decades. Available as a once-daily oral dose, this is a new option for patients. Learn more: https://ir.celgene.com/press-releases/press-release-details/2019/US-FDA-Approves-INREBIC-Fedratinib-as-First-New-Treatment-in-Nearly-a-Decade-for-Patients-With-Myelofibrosis/default.aspx
read more

Local pharmacist inspires patient-choice state law

August 27, 2019

JOHNS CREEK, Ga. The Pharmacy Anti-Steering and Transparency Act, which will go into effect Jan. 1, 2020, prohibits insurers and benefits managers who have ownership in a pharmacy from steering patients to that business. The law endeavors to reduce conflicts of interests, increase transparency and give patients more choice. The law was inspired in part […]
read more

Athenex Announces Oral Paclitaxel and Encequidar had a Significantly Higher Response Rate Over IV Paclitaxel in a Phase III Pivotal Study in Metastatic Breast Cancer

August 27, 2019

A recently published Phase III Trial by Athenex, Inc. showed that oral paclitaxel in combination with encequidar was superior to IV paclitaxel for Overall Response Rate in Metastatic Breast Cancer. Patients in the oral combination group also had less incidence of neuropathy than the intravenous group. Learn more at: https://ir.athenex.com/news-releases/news-release-details/athenex-announces-oral-paclitaxel-and-encequidar-had
read more

Arizona Blood & Cancer Specialists

August 15, 2019

MISSION STATEMENT / PHILOSOPHY: With experience, commitment and a shared vision of how we can positively impact patients’ lives, we’re changing the future of healthcare in our community. Understanding that each of our patients is a unique individual, our goal is to: provide the most advanced, clinically-proven treatments for their disease; provide access to clinical […]
read more

Oregon passes PBM legislation

August 7, 2019

On July 17th, the governor of Oregon signed a bill into the law; Oregon House Bill 2185 has been passed unanimously, imposing new requirements on Pharmacy Benefit Managers (PBMs) registered in Oregon. Effective January 1st, 2020, PBMs may not require a prescription to be filled or refilled by a mail order pharmacy if a dispensing […]
read more

White House drops Drug Rebate Reform

July 12, 2019

Although drug rebates have been an area of high focus for reform, the Trump Administration decided yesterday to withdraw its plan to eliminate rebates from government-sponsored drug plans. Read more
read more

Letter to the Committee on Finance – Phair Pricing Act (S.640)

July 2, 2019

Letter to the Committee on Finance – Phair Pricing Act (S.640) The Honorable Chuck Grassley Chairman Committee on Finance 135 Hart Senate Office Building United States Senate Washington, D.C. 20510 The Honorable Ron Wyden Ranking Member Committee on Finance 221 Dirksen Senate Office Building United States Senate Washington, D.C. 20510   Dear Chairman Grassley and […]
read more

CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer

July 2, 2019

Written by: Ann Schwemm, PharmD, MPH, BCOP, University of Minnesota Health Download Here Cyclin-dependent kinase (CDK) 4/6 inhibitors have demonstrated significant advances in the treatment of hormone receptor (HR) positive and human epidermal growth factor receptor (HER2) negative advanced breast cancer. While current available data do not support the preferential use of one agent over […]
read more

NCODA Patient Surveys Support the Need for Medically Integrated Pharmacies

June 20, 2019

Kirollos S. Hanna, PharmD, BCPS, BCOP Oral oncolytics, or oral chemotherapies, have significantly impacted the treatment of cancer. They enable patients to conveniently manage treatment in their homes. Despite the rapid growth, therapeutic advances, novel mechanisms of actions, and improved outcomes associated with these agents, the dispensing process remains inadequate. As a result of rising drug […]
read more

RESOURCES

Cost Avoidance Waste Tracker

Positive Quality Interventions

PQI in Action

OCE Sheets

IVE Sheets

Treatment Support Kits

PQI Podcast

Members

Member Resources

OPTA

Committees

Member Login

Events

Webinars

Spring Forum

Oncology Institute

PSO Annual Meeting

Fall Summit

contact@ncoda.org

315-655-4640

P.O. Box 468
Cazenovia, NY 13035

NCODA Logo

NCODA is a 501(c)(3) Organization